Sigyn Therapeutics to Present at the Life Sciences Virtual Investor Forum on September 18th

Sigyn Therapeutics, Inc. (OTCQB: SIGY), a pioneering developer of dialysis-like therapies targeting cardiovascular disease and cancer, is set to present at the Life Sciences Virtual Investor Forum on September 18th, 2025. The presentation will be led by Jim Joyce, the Company’s Chairman and CEO, and is scheduled for 3:00 PM ET. Investors will have the opportunity to engage in real-time Q&A during the live event, and an archived webcast will be available for those who cannot attend.

The Company's notable developments include the introduction of Sigyn Therapy™, an innovative device designed to decrease circulating inflammatory molecules and cholesterol-carrying lipoproteins linked to major adverse cardiovascular events (MACE). Given that cardiovascular disease is the leading cause of death globally, accounting for nearly one-third of annual fatalities, Sigyn's technology aims to significantly mitigate these risks. Sigyn Therapy™ employs a groundbreaking whole blood adsorption technology, targeting the extracorporeal removal of lipoprotein(a) [Lp(a)] and low-density lipoprotein cholesterol [LDL-C], which has shown to reduce adverse cardiovascular events by up to 98%.

In addition to its cardiovascular solutions, Sigyn Therapeutics is pursuing cutting-edge oncology treatments, including ImmunePrep™ for better immunotherapeutic delivery, ChemoPrep™ for enhanced chemotherapy targeting, and ChemoPure™ for reduced chemotherapy toxicity. The Company is focused on advancing these cancer therapies through strategic joint ventures.

Investors interested in engaging with the Company can schedule one-on-one meetings post-presentation, emphasizing the interactive nature of the event. For further information about the Company and its innovative therapies, visit www.SigynTherapeutics.com.

As Sigyn Therapeutics prepares for its presentation at the Life Sciences Virtual Investor Forum on September 18, 2025, investors should approach the company's stock (OTCQB: SIGY) with a discerning eye amid evolving market dynamics. The recent introduction of Sigyn Therapy™—an innovative first-in-class device targeting inflammatory molecules and lipid profiles linked to cardiovascular diseases—positions the company as a potential game-changer in a significant area of healthcare. Given that cardiovascular diseases account for nearly one-third of deaths globally, there is a burgeoning market for effective therapies in this sector.

Investors may want to pay attention to the company's dual focus on both cardiovascular and cancer therapies, as this diversified pipeline strengthens its growth story. The dialysis-like therapies, including thresholds for reducing the incidence of major adverse cardiovascular events (MACE) by a staggering 55% to 98%, enhance the company's clinical credibility. Coupled with their promising cancer therapies that improve both delivery and efficacy of treatments while reducing toxicity, Sigyn has the potential to appeal to a wide range of investors looking for impactful biotechnology solutions.

However, it is essential to consider market risks, including potential regulatory hurdles and competitive pressures from established players in the cardiovascular and oncology markets. Thus, engagement at the upcoming forum will be crucial for investors wishing to gain insights directly from leadership. The opportunity for interactive Q&A could clarify the company’s strategies and projected timelines, essential aspects for assessing risk vs. reward.

In conclusion, ahead of the investor forum, it’s advisable for prospective shareholders to evaluate Sigyn's technological differentiation, market needs, and innovation potential while remaining cognizant of the competitive landscape and regulatory environment. Pre-registration for the event and scheduling 1x1 meetings can provide invaluable insights that may influence investment decisions.